License and Collaboration Agreements - Additional Information (Detail)		1 Months Ended			4 Months Ended	8 Months Ended	12 Months Ended			35 Months Ended	56 Months Ended
	Oct. 03, 2014 USD ($)	Dec. 31, 2014 USD ($)	Oct. 31, 2014 USD ($) Installment	Jul. 31, 2007 USD ($)	May. 04, 2010 USD ($)	Dec. 31, 2010 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	May. 04, 2010 USD ($)	Dec. 31, 2013 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Gain on disposition of stock								$ 4,768,000
License and collaboration revenue							$ 6,277,000	49,692,000	$ 323,000
Collaborative Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds from collaborators				$ 75,000,000	$ 12,800,000					$ 53,500,000
Percentage of global development costs funded by each party in collaboration										50.00%
License Agreement Terms
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Amount received upon execution of the agreement						$ 50,000,000
Percentage of costs funded in the license agreement							100.00%
License Agreement Terms | Sarcoma
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds from regulatory or sales milestone payments											$ 25,000,000
Otsuka Pharmaceutical Co. Ltd
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Term of license fee							10 years
Otsuka Pharmaceutical Co. Ltd | Japan
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Refundable withholding tax							$ 15,800,000
Otsuka Pharmaceutical Co. Ltd | License agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Amount received upon execution of the agreement							77,500,000
Otsuka Pharmaceutical Co. Ltd | License agreement | Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Additional milestone payments							80,000,000
Bellicum Pharmaceuticals Inc | License agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Amount received upon execution of the agreement			$ 15,000,000
License agreement, amount of agreement			$ 50,000,000
Number of Installments | Installment			3
Gain on disposition of stock	$ 4,768,000
License and collaboration revenue								$ 45,200,000
Bellicum Pharmaceuticals Inc | License agreement | due by June 30, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Installment amount			$ 20,000,000
Bellicum Pharmaceuticals Inc | License agreement | due by June 30, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Installment amount			$ 15,000,000
Bellicum Pharmaceuticals Inc | License agreement | Payment One
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds from collaborators		$ 20,000,000
Bellicum Pharmaceuticals Inc | License agreement | Payment Two
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds from collaborators		$ 15,000,000
Medinol Ltd. | License agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments for clinical trials							3,800,000
Medinol Ltd. | License agreement | Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Additional milestone payments							$ 34,800,000